AR and pachyonychia congenita: AR binding undergoes significant reprogramming during PC pathogenesis and progression, resulting in gains and losses of AR binding sites (ARBS), and ARBS that are specific to benign prostate, primary PC, and CRPC tumors have been identified (12, 13).